Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1326 • 2012 ACR/ARHP Annual Meeting
Efficacy of Different Biologic Agents for Improving Physical Function As Measured by the Health Assessment Questionnaire: A Meta-Analysis with Indirect Comparisons
Lillian J. Barra¹, Andrew Ha², Louise Sun³, Catarina Fonseca⁴ and Janet E. Pope⁵, ¹Medicine, Division of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ²The University of Toronto, Toronto, ON, Canada, ³University of Ottawa, Ottawa, ON, Canada, ⁴Universidade de Lisboa, Lisbon, Portugal, ⁵Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: The Health Assessment Questionnaire (HAQ) is a patient-centred, validated measure of physical function. It is predictive for disability, morbidity and mortality. The efficacy…
Abstract Number: 494 • 2012 ACR/ARHP Annual Meeting
Are There Gender Specific Differences in Patient Characteristics At Initiation of Biologic Treatment in Rheumatoid Arthritis?
William Bensen¹, Denis Choquette², Isabelle Fortin³, Alice V. Klinkhoff⁴, Susan M. Otawa⁵ and Hayssam Khalil⁶, ¹St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ²Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴The Mary Pack Arthritis Ctr, Vancouver, BC, Canada, ⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁶Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) is 2-4 times higher in women compared to men depending on age. Furthermore, in women RA incidence increases…
Abstract Number: 195 • 2012 ACR/ARHP Annual Meeting
Inflammatory Arthritis in Patients with Myelodysplastic Syndrome: French Multicenter Retrospective Study
Arsene Mekinian¹, Olivier Decaux², Geraldine Falgarone³, Thorsten Braun Sr.⁴, Eric Toussirot⁵, Loic Raffray⁶, Bruno Gombert⁷, Bruno de Wazieres⁸, Anne Laure Buchdaul⁹, Jean-Marc Ziza¹⁰, David Launay¹¹, Guillaume Denis¹², Serge Madaule¹³, Pierre Fenaux¹⁴ and Olivier Fain¹⁵, ¹Internal Medicine, Jean Verdier Hospital, Bondy, FL, France, ²Department of Internal Medicine, Rennes University Hospital, Rennes, France, ³Rheumatology, Hopital avicenne, Paris, France, ⁴Hematology, Avicenne hospital, Bobigny, France, ⁵Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, ⁶Internal Medicine, CHU de Bordeaux, Bordeaux, France, ⁷Internal Medicine, La Rochelle hospital, La Rochelle, France, ⁸Internal Medecine, CHU de Nimes, Nimes, France, ⁹Internal Medicine, Douai hospital, Douai, France, ¹⁰Rheumatology, Croix Saint Simon Hospital, Paris, France, ¹¹Internal Medicine, Claude Huriez University Hospital, Lille, France, ¹²Internal Medicine, Rochefoucault hospital, Rochefoucault, France, ¹³Rheuamtology, Albi hospital, Albi, France, ¹⁴Hematology, Avicenne Hospital, France, ¹⁵Internal Medicine, Jean Verdier Hospital, Bondy, France
Inflammatory arthritis in patients with myelodysplastic syndrome: French multicenter retrospective study.For the Société Nationale Française de Médecine Interne (SNFMI), the CRI (Club Rhumatismes Inflammation) and…
Abstract Number: 2107 • 2012 ACR/ARHP Annual Meeting
Assessing Subclinical Synovitis in Rheumatoid Arthritis: Arthrosonographic Findings in Patients with Good Response to Therapy
Matthias Witt¹, Felix Mueller², Axel Nigg², Christiane Reindl³, Hendrik Schulze-Koops² and Mathias Grunke², ¹Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Division of Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ³Division for Rheumatology, Division of Rheumatology and Clinical Immunology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany
Background/Purpose: Treat-to-target is a key principle in rheumatoid arthritis. Composite scores such as the DAS-28 help to monitor disease activity and response to therapy. However,…
Abstract Number: 1310 • 2012 ACR/ARHP Annual Meeting
Analysis of Anti-JC Polyomavirus T-Cell Immune Response with JC-Feron in Patients with Rheumatoid Arthritis Treated with Rituximab or Anti-TNF
Raphaèle Seror¹, Houria Chavez², anne-Aurélie Mazet³, Jeremie Sellam⁴, Bruno Fautrel⁵, Maxime Dougados⁶, Yassine Taoufik² and Xavier Mariette⁷, ¹Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Virology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology, Hopital Saint-Antoine, Pierre et Marie Curie University Paris 6, AP-HP, 75012, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: Some cases of progressive multifocal leukoencephalopathy (PML) have been described in patients with autoimmune diseases with profound immunosuppression, due to replication of JC polyomavirus…
Abstract Number: 502 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Rituximab in Patients with Rheumatoid Arthritis and Lung Involvement
Elena Becerra¹, Geraldine Cambridge² and Maria J. Leandro², ¹Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom
Background/Purpose: Lung involvement is common in patients with Rheumatoid Arthritis (RA), including interstitial lung disease (ILD), pleural disease and small airway disease. There are no…
Abstract Number: 110 • 2012 ACR/ARHP Annual Meeting
Comparing Palmar and Dorsal Ultrasound Assessment of Small Joint Synovitis in Rheumatoid Arthritis: Dorsal Greyscale Mode Yields Significantly Better Concordance with Power Doppler
Matthias Witt¹, Felix Mueller¹, Hendrik Schulze-Koops² and Mathias Grunke³, ¹Division of Rheumatology, Medizinische Klinik und Poliklinik IV, University of Munich, Munich, Germany, ²Division of Rheumatology, University of Munich, Munich, Germany, ³Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany
Background/Purpose: MCP and PIP joints are frequently involved in rheumatoid arthritis. Complete ultrasound assessment of these joints requires the palmar and the dorsal approach for…
Abstract Number: 2098 • 2012 ACR/ARHP Annual Meeting
Patient Report Outcomes Variance Between Centers Is Much Lower Than Physician and Laboratory Assessed Measures of Rheumatoid Arthritis Activity: Results From a Multinational Study
Nasim A. Khan¹, Horace Spencer², Tuulikki Sokka³ and QUEST-RA⁴, ¹Rheumatology, University of Arkansas for Medical Sciences and Central Arkansas Veterans Healthcare System, Little Rock, AR, ²University of Arkansas for Medical Sciences, Little Rock, AR, ³Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁴Jyväskylä
Background/Purpose: Clinical trials and epidemiological rheumatoid arthritis (RA) studies often recruit patients from multiple centers. We studied the proportion of variance in the American…
Abstract Number: 1288 • 2012 ACR/ARHP Annual Meeting
A Significant Number of Patients with Chronic Arthritis Received a Reduced Dosage of Biological Drugs: an Observational Study in Clinical Practice
Jose Inciarte-Mundo¹, Maria Victoria Hernández², Violeta Rosario¹, Sonia Cabrera¹, Virginia Ruiz-Esquide³, Maria Eugenia Gomez-Caballero¹, Jose A. Gómez-Puerta¹, Julio Ramirez¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Biological agents are used to treat chronic arthritis according to the standard dosages from phase III clinical trials. However, in some patients, a good…
Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Patrick Durez¹, Pedro Miranda², Antoaneta Toncheva³, Alberto Berman Sr.⁴, Oscar L. Rillo⁵, Yves Boutsen⁶, Tatjana Kehler⁷, Eugenia Mociran⁸, LiAn Soto Saez⁹, Bruno Fautrel¹⁰, Xavier Mariette¹¹, Panayot Solakov¹², Eleonora Lucero¹³, Tonko Vlak¹⁴, Simeon Grazio¹⁵, Ksenija Mastrovic¹⁶, Rodica Chiriac¹⁷, Géraldine Grouard-Vogel¹⁸, Olivier Dhellin¹⁸, Stéphane Ouary¹⁸, Pierre Vandepapeliere¹⁸ and Marie-Christophe Boissier¹⁹, ¹Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ²Universidad de Chile and Centro de Estudios Reumatologicos, Santiago de Chile, Chile, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Internal Medicine, Hospital Padilla, Tucuman, Argentina, ⁵Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁶UCL Mont-Godinne, Godinne, Belgium, ⁷Thalassotherapia Opatija, Opatija, Croatia, ⁸Emergency County Hospital Dr Constantin Opis, Maramures, Romania, ⁹Sociedad Medica del Aparato Locomotor SA, Santiago de Chile, Chile, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹²Plovdiv, Diagnostic and Consulting Center, Plovdiv, Bulgaria, ¹³Rheumatology Unit, Padilla Hospital, Tucumán, Argentina, ¹⁴University Hospital Split, Split, Croatia, ¹⁵Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁶Clinical Hospital Sveti Duh, Zagreb, Croatia, ¹⁷Rehabilitation clinical Hospital Iasi, Iasi, Romania, ¹⁸NEOVACS SA, Paris, France, ¹⁹Dept of Rheumatology, Hopital Avicenne, Bobigny, France
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…
Abstract Number: 112 • 2012 ACR/ARHP Annual Meeting
Time-Integrated Synovitis Activity Assessed by Power Doppler Ultrasound Significantly Correlates with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Methotrexate Alone but Not in Those Treated with TNF Antagonists
Kei Ikeda, Daiki Nakagomi, Yoshie Sanayama, Mieko Yamagata, Ayako Okubo, Taro Iwamoto, Hirotoshi Kawashima, Kentaro Takahashi and Hiroshi Nakajima, Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
Background/Purpose: Although a number of studies have shown a higher sensitivity of ultrasound than clinical joint examination in detecting synovitis in patients with rheumatoid arthritis…
Abstract Number: 2099 • 2012 ACR/ARHP Annual Meeting
Patient Self-Assessments and Selected Patient Reported Outcomes May Reliably Identify Rheumatoid Disease Flare in Early Rheumatoid Arthritis Patients
Vivian P. Bykerk¹, Clifton O. Bingham III², Ernest Choy³, Juan Xiong⁴, Gilles Boire⁵, Carol A. Hitchon⁶, Janet E. Pope⁷, J. Carter Thorne⁸, Boulos Haraoui⁹, Edward Keystone¹⁰ and Susan J. Bartlett¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹Clinical Epidemiology, McGill University, Montreal, QC, Canada
Background/Purpose: Significant RA worsening or flare may predict poorer outcomes and signal a need for treatment reassessment. However, there is little agreement about how to…
Abstract Number: 1293 • 2012 ACR/ARHP Annual Meeting
Importance of Steady-State Trough Concentrations After Intravenous Golimumab with Concomitant Methotrexate in Subjects with Active Rheumatoid Arthritis
J. H. Leu¹, Z. Xu¹, C. Hu¹, Alan Mendelsohn¹, J. Ford¹, Hugh M. Davis² and H. Zhou¹, ¹Janssen Research and Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To determine an optimized dosing regimen for IV golimumab in subjects with active RA using population pharmacokinetic (PK) modeling and simulation. Methods: Two Phase…
Abstract Number: 489 • 2012 ACR/ARHP Annual Meeting
The Comparative Effectiveness of Anti-TNF Medications Among Older and Disabled Rheumatoid Arthritis Patients in the U.S. Medicare Population
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell³, Lang Chen⁴, Shuo Yang⁵, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Health Care Organization & Policy, University of Alabama-Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁷Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Evaluating the real world effectiveness of biologic DMARDs in rheumatoid arthritis (RA) patients using administrative claims data has previously not been feasible due to…
Abstract Number: 114 • 2012 ACR/ARHP Annual Meeting
US Examination of Wrists and Hands: A Comparison Between Rheumatoid Arthritis and Psoriatic Arthritis
Andrea Delle Sedie¹, Elisa Cioffi¹, Linda Carli², Elena Sardano³, Stefano Bombardieri¹ and Lucrezia Riente¹, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Immunology Unit, University of Pisa, Immunology Unit, University of Pisa, Italy
Background/Purpose: very little is known about the differences in joint and periarticular structure involvement in rheumatoid or psoriatic arthritis (PsA). The main pathological features detected…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].